Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Jia Jin, Kee"'
Autor:
Yunda Huang, Oleg Borisov, Jia Jin Kee, Lindsay N. Carpp, Terri Wrin, Suqin Cai, Marcella Sarzotti-Kelsoe, Charlene McDanal, Amanda Eaton, Rolando Pajon, John Hural, Christine M. Posavad, Katherine Gill, Shelly Karuna, Lawrence Corey, M. Juliana McElrath, Peter B. Gilbert, Christos J. Petropoulos, David C. Montefiori
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Abstract Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated with vaccine efficacy. In United States government-sponsored phase 3 efficacy trials of COVID-19 vaccines, nAbs are measured by two different valid
Externí odkaz:
https://doaj.org/article/a8fc55db2c1244ab80f29f9a5f6dcf24
Autor:
Zoe Moodie, One Dintwe, Sheetal Sawant, Doug Grove, Yunda Huang, Holly Janes, Jack Heptinstall, Faatima Laher Omar, Kristen Cohen, Stephen C De Rosa, Lu Zhang, Nicole L Yates, Marcella Sarzotti-Kelsoe, Kelly E Seaton, Fatima Laher, Linda Gail Bekker, Mookho Malahleha, Craig Innes, Sheetal Kassim, Nivashnee Naicker, Vaneshree Govender, Modulakgotla Sebe, Nishanta Singh, Philip Kotze, Erica Lazarus, Maphoshane Nchabeleng, Amy M Ward, William Brumskine, Thozama Dubula, April K Randhawa, Nicole Grunenberg, John Hural, Jia Jin Kee, David Benkeser, Yutong Jin, Lindsay N Carpp, Mary Allen, Patricia D’Souza, James Tartaglia, Carlos A DiazGranados, Marguerite Koutsoukos, Peter B Gilbert, James G Kublin, Lawrence Corey, Erica Andersen-Nissen, Glenda E Gray, Georgia D Tomaras, M Juliana McElrath
Publikováno v:
J Infect Dis
Background The ALVAC/gp120 + MF59 vaccines in the HIV Vaccine Trials Network (HVTN) 702 efficacy trial did not prevent human immunodeficiency virus-1 (HIV-1) acquisition. Vaccine-matched immunological endpoints that were correlates of HIV-1 acquisiti
Autor:
Gustavo H, Dayan, Nadine, Rouphael, Stephen R, Walsh, Aiying, Chen, Nicole, Grunenberg, Mary, Allen, Johannes, Antony, Kwaku Poku, Asante, Amit Suresh, Bhate, Tatiana, Beresnev, Matthew I, Bonaparte, Maria, Angeles Ceregido, Dmytro, Dobrianskyi, Bo, Fu, Marie-Helene, Grillet, Maryam, Keshtkar-Jahromi, Michal, Juraska, Jia Jin, Kee, Hannah, Kibuuka, Marguerite, Koutsoukos, Roger, Masotti, Nelson L, Michael, Humberto, Reynales, Merlin L, Robb, Sandra M, Villagómez Martínez, Fredrick, Sawe, Lode, Schuerman, Tina, Tong, John, Treanor, T Anh, Wartel, Carlos A, Diazgranados, Roman M, Chicz, Sanjay, Gurunathan, Stephen, Savarino, Saranya, Sridhar
Publikováno v:
medRxiv : the preprint server for health sciences.
BackgroundCOVID-19 vaccines with alternative strain compositions are needed to provide broad protection against newly emergent SARS-CoV-2 variants of concern.MethodsWe conducted a global Phase 3, multi-stage efficacy study (NCT04904549) among adults
Autor:
One B Dintwe, Stephen C De Rosa, Yunda Huang, Britta S Flach, Bryce Manso, Don Carter, Faatima Laher Omar, Katharine V Schwedhelm, Chenchen Yu, Huiyin Lu, Daryl Morris, Jia Jin Kee, Valentin Voillet, Michael Stirewalt, John Hural, Zoe Moodie, Nicole Frahm, Kristen W Cohen, M Juliana McElrath, Erica Andersen-Nissen
Publikováno v:
J Leukoc Biol
The HIV Vaccine Trials Network (HVTN) conducts clinical trials on 4 continents in pursuit of a safe and effective HIV vaccine. Cellular immune responses to vaccination that define vaccine immunogenicity and/or immune correlates of protection can be m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::41ef08794df571dc8dfc716b49d7d593
https://europepmc.org/articles/PMC10229754/
https://europepmc.org/articles/PMC10229754/
Autor:
Christine M. Posavad, David C. Montefiori, Suqin Cai, Amanda Eaton, Rolando Pajon, Yunda Huang, Peter B. Gilbert, Lindsay N. Carpp, Jia Jin Kee, Shelly Karuna, M. Juliana McElrath, Lawrence Corey, Christos J. Petropoulos, Terri Wrin, Charlene McDanal, Oleg Borisov, Marcella Sarzotti-Kelsoe, Katherine Gill, John Hural
Publikováno v:
Research Square
article-version (status) pre
article-version (number) 1
medRxiv
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
article-version (status) pre
article-version (number) 1
medRxiv
Scientific Reports
Scientific Reports, Vol 11, Iss 1, Pp 1-13 (2021)
Vaccine-induced neutralizing antibodies (nAbs) are key biomarkers considered to be associated with vaccine efficacy. In United States Government-sponsored phase 3 efficacy trials of COVID-19 vaccines, nAbs are measured by two different validated pseu
Autor:
Peter B. Rupert, Meei-Li Huang, Haiying Zhu, Andrew Fiore-Gartland, Arnold Park, Colleen McLaughlin, Chance Brock, April K. Randhawa, Roland K. Strong, Maurine D. Miner, Yixuan J. Hou, Matthew Buerger, Ralph S. Baric, Emily S Ford, Leonidas Stamatatos, Anton M Sholukh, Hannah Kaiser, Russell St Germain, Florian A. Lempp, Keith R. Jerome, Andrew B. Stuart, Joyce Y C Lu, Emily L Bossard, Bhanupriya Madarampalli, Margaret K. Doll, Jia Jin Kee, Kurt Diem, Lawrence Corey, Longping V. Tse, David C. Montefiori
Publikováno v:
Journal of Clinical Microbiology
Determinants of protective immunity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection require the development of well-standardized, reproducible antibody assays. This need has led to the emergence of a variety of neutrali
Autor:
Kurt Diem, Yixuan J. Hou, Emily S Ford, Leonidas Stamatatos, Peter B. Rupert, Anton M Sholukh, Roland K. Strong, Russell Saint Germain, Ralph S. Baric, Andrew B. Stuart, Chance Brock, Margaret K. Doll, April K. Randhawa, Matthew Buerger, Jia Jin Kee, Lawrence Corey, Keith R. Jerome, Andrew Fiore-Gartland, Hanna Kaiser, Florian A. Lempp, Emily L Bossard, Longping V. Tse, David C. Montefiori, Colleen McLaughlin
Publikováno v:
medRxiv
Determinants of protective immunity against SARS-CoV-2 infection require the development of well-standardized, reproducible antibody assays to be utilized in concert with clinical trials to establish correlates of risk and protection. This need has l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0657f8b73bf92be48fc49da6a215efdd
https://doi.org/10.1101/2020.12.07.20245431
https://doi.org/10.1101/2020.12.07.20245431
Autor:
Thomas Goldner, Craig A. Magaret, Susanne Stoelben, Burkhard Timmler, Alexander Birkmann, Lawrence Corey, Holger Zimmermann, Anna Wald, Kurt Diem, Jia Jin Kee, Paul T. Edlefsen, Helga Ruebsamen-Schaeff, Meei Li Huang, Terri Warren
Publikováno v:
The Journal of Infectious Diseases
Pritelivir (also known as BAY 57–1293 and AIC316) belongs to a new class of antiviral compounds, the helicase-primase inhibitors (HPIs), that prevent the de novo synthesis of virus DNA through inhibition of the helicase-primase complex [1]. Functio
Autor:
Edlefsen, Paul T., Birkmann, Alexander, Meei-Li Huang, Magaret, Craig A., Jia Jin Kee, Diem, Kurt, Goldner, Thomas, Timmler, Burkhard, Stoelben, Susanne, Ruebsamen-Schaeff, Helga, Zimmermann, Holger, Warren, Terri, Wald, Anna, Corey, Lawrence, Huang, Meei-Li, Kee, Jia Jin
Publikováno v:
Journal of Infectious Diseases; 7/15/2016, Vol. 214 Issue 2, p258-264, 7p